TPST
Tempest Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$22.38M
P/E Ratio
—
EPS
$-6.33
Beta
-1.89
52W High
$12.23
52W Low
$1.50
50-Day MA
$2.26
200-Day MA
$6.08
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Tempest Therapeutics Inc
Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-26.31M |
| Operating Margin | 0.00% |
| Return on Equity | -203.60% |
| Return on Assets | -56.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.35 |
| Price-to-Book | 3.39 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.31 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $14.34M |
| Float | $9.27M |
| % Insiders | 35.37% |
| % Institutions | 29.41% |
Historical Volatility
HV 10-Day
85.35%
HV 20-Day
101.66%
HV 30-Day
87.65%
HV 60-Day
83.08%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($11.00 target)
1
BuyData last updated: 4/9/2026